Tubulin: An example of targeted chemotherapy

Future Medicinal Chemistry

Volumn 5, Issue 3, 2013, Pages 339-352

  Seligmann, Jenny ^a   Twelves, Chris ^a  

^a ST JAMES S UNIVERSITY HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

21 AMINOEPOTHILONE B; 9,10 DIDEHYDROEPOTHILONE D; ALPHA TUBULIN; ANTHRACYCLINE DERIVATIVE; ANTIMITOTIC AGENT; ANTINEOPLASTIC AGENT; BETA TUBULIN; BIOLOGICAL MARKER; BMS 31075; CABAZITAXEL; COLCHICINE DERIVATIVE; COMBRETASTATIN; CRYPTOPHYCIN DERIVATIVE; DISCODERMOLIDE; ELEUTHEROBIN; EPIPODOPHYLLOTOXIN DERIVATIVE; EPOTHILONE D; EPOTHILONE DERIVATIVE; ERIBULIN; ESTRAMUSTINE; GLUTATHIONE TRANSFERASE P1; IXABEPILONE; LAULIMALIDE; MICROTUBULE PROTEIN; MICROTUBULE TARGETING AGENT; PACLITAXEL; PROTEIN BCL X; PROTEIN MCL 1; SAGOPILONE; STEROID; TAXANE DERIVATIVE; TRASTUZUMAB EMTANSINE; TUBULIN; UNCLASSIFIED DRUG; UNINDEXED DRUG; VINCA ALKALOID;

AMINOTRANSFERASE BLOOD LEVEL; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; BREAST CANCER; BREAST METASTASIS; CANCER CHEMOTHERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER PATIENT; CANCER RESISTANCE; CASTRATION RESISTANT PROSTATE CANCER; CELL DIVISION; CELL PROLIFERATION; CYTOTOXICITY; DRUG DELIVERY SYSTEM; DRUG DESIGN; DRUG EFFICACY; DRUG FORMULATION; DRUG HYPERSENSITIVITY; DRUG MECHANISM; DRUG MEGADOSE; DRUG METABOLISM; DRUG PENETRATION; DRUG SAFETY; DRUG SOLUBILITY; DRUG STABILITY; DRUG TARGETING; DRUG WITHDRAWAL; FATIGUE; FEBRILE NEUTROPENIA; HEAD AND NECK CANCER; HUMAN; HYPONATREMIA; IN VITRO STUDY; IN VIVO STUDY; KIDNEY CANCER; LUNG NON SMALL CELL CANCER; MICROTUBULE; MICROTUBULE ASSEMBLY; MITOSIS; MITOSIS SPINDLE; MOLECULAR DYNAMICS; MOLECULARLY TARGETED THERAPY; MONOTHERAPY; MULTICENTER STUDY (TOPIC); MUSCLE WEAKNESS; NEOPLASM; NEUROPATHIC PAIN; NEUROPATHY; NEUTROPENIA; NONHODGKIN LYMPHOMA; NONHUMAN; OVERALL SURVIVAL; PARESTHESIA; PERIPHERAL NEUROPATHY; PHASE 3 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; PROSTATE CANCER; REVIEW; SIDE EFFECT; THROMBOCYTOPENIA; TREATMENT RESPONSE; TUMOR XENOGRAFT;

ANIMALS; ANTINEOPLASTIC AGENTS; DRUG DELIVERY SYSTEMS; DRUG RESISTANCE, NEOPLASM; HUMANS; MOLECULAR TARGETED THERAPY; NEOPLASMS; TAXOIDS; TUBULIN; TUBULIN MODULATORS;

EID: 84874716334     PISSN: 17568919     EISSN: 17568927     Source Type: Journal    
DOI: 10.4155/fmc.12.217     Document Type: Review

References (129)

1. Nogales E. Structural insight into microtubule function. Annu. Rev. Biophys. Biomol. Struct. 30, 397-420 (2001).
2. Komlodi-Pasztor E, Sackett D, Wilkerson J, Fojo T. Mitosis is not a key target of microtubule agents in patient tumors. Nat. Rev. Clin. Oncol. 8(4), 244-250 (2011).
3. Komlodi-Pasztor E, Sackett DL, Fojo AT. Inhibitors targeting mitosis: tales of how great drugs against a promising target were brought down by a flawed rationale. Clin. Cancer Res. 18(1), 51-63 (2012).
4. Dumontet C, Jordan MA, Microtubule-binding agents: a dynamic field of cancer therapeutics. Nat. Rev. Drug Discov. 9(10), 790-803 (2010).
5. Kanthou C, Tozer GM. Tumour targeting by microtubule-depolymerizing vascular disrupting agents. Expert Opin. Ther. Target 11(11), 1443-1457 (2007).
6. Etienne-Manneville S. From signaling pathways to microtubule dynamics: the key players. Curr. Opin. Cell Biol. 22(1), 104-111 (2010).
7. Pasquier E, Carré M, Pourroy B et al. Antiangiogenic activity of paclitaxel is associated with its cytostatic effect, mediated by the initiation but not completion of a mitochondrial apoptotic signaling pathway. Mol. Cancer Ther. 3(10), 1301-1310 (2004).
8. Tran TA, Gillet L, Roger S, Besson P, White E, Le Guennec JY. Non-anti-mitotic concentrations of taxol reduce breast cancer cell invasiveness. Biochem. Biophys. Res. Commun. 379(2), 304-308 (2009).
9. Wertz IE, Kusam S, Lam C. Sensitivity to antitubulin chemotherapeutics is regulated by MCL1 and FBW7. Nature 471(7336), 110-114 (2011).
10. Seidman AD. 'Will weekly work'? Seems to be so. J. Clin. Oncol. 23(25), 5873-5874 (2005).
11. Sparreboom A, van Zuylen L, Brouwer E. Cremophor EL-mediated alteration of paclitaxel distribution in human blood: clinical pharmacokinetic implications. Cancer Res. 59(7), 1454-1457 (1999).
12. ten Tije AJ, Verweij J, Loos WJ, Sparreboom A. Pharmacological effects of formulation vehicles: implications for cancer chemotherapy. Clin. Pharmacokinet. 42(7), 665-685 (2003).
13. DeAngelis LM, Gnecco C, Taylor L, Warrell RP Jr. Evolution of neuropathy and myopathy during intensive vincristine/corticosteroid chemotherapy for non-Hodgkin's lymphoma. Cancer 67(9), 2241-2246 (1991).
14. Cavaletti G, Marmiroli P. Chemotherapy-induced peripheral neurotoxicity. Nat. Rev. Neurol. 6(12), 657-666 (2010).
15. Lee JJ, Swain SM. Peripheral neuropathy induced by microtubule- stabilizing agents. J. Clin. Oncol. 24(10), 1633-1642 (2006).
16. Shemesh OA, Spira ME. Paclitaxel induces axonal microtubules polar reconfiguration and impaired organelle transport: implications for the pathogenesis of paclitaxel-induced polyneuropathy. Acta. Neuropathol. 119(2), 235-248 (2010).
17. Persohn E, Canta A, Schoepfer S. Morphological and morphometric analysis of paclitaxel and docetaxel-induced peripheral neuropathy in rats. Eur. J. Cancer 41(10), 1460-1466 (2005).
18. Alexandre J, Batteux F, Nicco C et al. Accumulation of hydrogen peroxide is an early and crucial step for paclitaxel-induced cancer cell death both in vitro and in vivo. Int. J. Cancer 119(1), 41-48 (2006).
19. Mir O, Alexandre J, Tran A et al. Relationship between GSTP1 Ile(105)Val polymorphism and docetaxel-induced peripheral neuropathy: clinical evidence of a role of oxidative stress in taxane toxicity. Ann. Oncol. 20(4), 736-740 (2009).
20. Peters C.M, Jimenez-Andrade JM, Jonas BM et al. Intravenous paclitaxel administration in the rat induces a peripheral sensory neuropathy characterized by macrophage infiltration and injury to sensory neurons and their supporting cells. Exp. Neurol. 203(1), 42-54 (2007).
21. Sahenk Z, Brady ST, Mendell Jr. Studies on the pathogenesis of vincristine-induced neuropathy. Muscle Nerve 10(1), 80-84 (1987).
22. Topp KS, Tanner KD, Levine JD. Damage to the cytoskeleton of large diameter sensory neurons and myelinated axons in vincristine-induced painful peripheral neuropathy in the rat. J. Comp. Neurol. 424(4), 563-576 (2000).
23. Sissung TM, Mross K, Steinberg SM et al. Association of ABCB1 genotypes with paclitaxel-mediated peripheral neuropathy and neutropenia. Eur. J. Cancer 42(17), 2893-2896 (2006).
24. Cascinu S, Catalano V, Cordella L et al. Neuroprotective effect of reduced glutathione on oxaliplatin-based chemotherapy in advanced colorectal cancer: a randomized, double-blind, placebo-controlled trial. J. Clin. Oncol. 20(16), 3478-3483 (2002).
25. Loven D, Levavi H, Sabach G et al. Long-term glutamate supplementation failed to protect against peripheral neurotoxicity of paclitaxel. Eur. J. Cancer Care (Engl.) 18(1), 78-83 (2009).
26. Pachman DR, Barton DL, Watson JC, Loprinzi CL. Chemotherapy-induced peripheral neuropathy: prevention and treatment. Clin. Pharmacol. Ther. 90(3), 377-387 (2011).
27. Horwitz SB, Cohen D, Rao S, Ringel I, Shen HJ, Yang CP. Taxol: mechanisms of action and resistance. Ann. NY Acad. Sci. 466, 733-744 (1986).
28. Kavallaris M. Microtubules and resistance to tubulin-binding agents. Nat. Rev. Cancer 10(3), 194-204 (2010).
29. Bollag DM, McQueney PA, Zhu J et al. Epothilones, a new class of microtubule-stabilizing agents with a taxol-like mechanism of action. Cancer Res. 55(11), 2325-2333 (1995).
30. Pepe A, Sun L, Zanardi I et al. Novel C-seco-taxoids possessing high potency against paclitaxel-resistant cancer cell lines overexpressing class III beta-tubulin. Bioorg. Med. Chem. Lett. 19(12), 3300-3304 (2009).
31. Dumontet C, Jordan MA, Lee FF. Ixabepilone: targeting betaIII-tubulin expression in taxane-resistant malignancies. Mol. Cancer Ther.8(1), 17-25 (2009).
32. Seve P, Dumontet C. Is class III beta-tubulin a predictive factor in patients receiving tubulin-binding agents? Lancet Oncol. 9(2), 168-175 (2008).
33. Hari M, Yang H, Zeng C, Canizales M, Cabral F. Expression of class III beta-tubulin reduces microtubule assembly and confers resistance to paclitaxel. Cell Motil. Cytoskeleton 56(1), 45-56 (2003).
34. Derry WB, Wilson L, Khan IA, Luduena RF, Jordan MA. Taxol differentially modulates the dynamics of microtubules assembled from unfractionated and purified beta-tubulin isotypes. Biochemistry 36(12), 3554-3562 (1997).
35. Kamath K, Wilson L, Cabral F, Jordan MA. Beta III-tubulin induces paclitaxel resistance in association with reduced effects on microtubule dynamic instability. J. Biol. Chem. 280(13), 12902-12907 (2005).
36. Kavallaris M, Kuo DY, Burkhart CA et al. Taxol-resistant epithelial ovarian tumors are associated with altered expression of specific beta-tubulin isotypes. J. Clin. Invest. 100(5), 1282-1293 (1997).
37. Ranganathan S, Benetatos CA, Colarusso PJ, Dexter DW, Hudes GR. Altered beta-tubulin isotype expression in paclitaxel-resistant human prostate carcinoma cells. Br. J. Cancer 77(4), 562-566 (1998).
38. Burkhart CA, Kavallaris M, Horwitz S. The role of beta-tubulin isotypes in resistance to antimitotic drugs. Biochim. Biophys. Acta 1471(2), O1-O9 (2001).
39. Kavallaris M, Kuo DY, Burkhart CA. Taxol-resistant epithelial ovarian tumors are associated with altered expression of specific beta-tubulin isotypes. J. Clin. Invest. 100(5), 1282-1293 (1997).
40. Kavallaris M, Tait AS, Walsh BJ. Multiple microtubule alterations are associated with Vinca alkaloid resistance in human leukemia cells. Cancer Res. 61(15), 5803-5809 (2001).
41. Rosell R, Scagliotti G, Danenberg KD. Transcripts in pretreatment biopsies from a three-arm randomized trial in metastatic non-small-cell lung cancer. Oncogene 22(23), 3548-3553 (2003).
42. Sève P, Isaac S, Trédan O et al. Expression of class III {beta}-tubulin is predictive of patient outcome in patients with non-small cell lung cancer receiving vinorelbine-based chemotherapy. Clin. Cancer Res. 11(15), 5481-5486 (2005).
43. Sève P, Mackey J, Isaac S et al. Class III beta-tubulin expression in tumor cells predicts response and outcome in patients with non-small cell lung cancer receiving paclitaxel. Mol. Cancer Ther. 4(12), 2001-2007 (2005).
44. Azuma K, Sasada T, Kawahara A et al. Expression of ERCC1 and class III beta-tubulin in non-small cell lung cancer patients treated with carboplatin and paclitaxel. Lung Cancer 64(3), 326-333 (2009).
45. Vilmar AC, Santoni-Rugiu E, Sørensen JB. Class III beta-tubulin in advanced NSCLC of adenocarcinoma subtype predicts superior outcome in a randomized trial. Clin. Cancer Res. 17(15), 5205-5214 (2011).
46. Butts CA, Ding K, Seymour L et al. Randomized Phase III trial of vinorelbine plus cisplatin compared with observation in completely resected stage IB and II non-small-cell lung cancer: updated survival analysis of JBR-10. J. Clin. Oncol. 28(1), 29-34 (2010).
47. Sève P, Dumontet C. Is class III beta-tubulin a predictive factor in patients receiving tubulin-binding agents? Lancet Oncol. 9(2), 168-175 (2008).
48. Reiman T, Lai R, Veillard AS et al. Cross-validation study of class III beta-tubulin as a predictive marker for benefit from adjuvant chemotherapy in resected non-small-cell lung cancer: analysis of four randomized trials. Ann. Oncol. 23(1), 86-93 (2011).
49. Paradiso A, Mangia A, Chiriatti A et al. Biomarkers predictive for clinical efficacy of taxol-based chemotherapy in advanced breast cancer. Ann. Oncol. 16(Suppl. 4), iv14-iv19 (2005).
50. Tommasi S, Mangia A, Lacalamita R et al. Cytoskeleton and paclitaxel sensitivity in breast cancer: the role of beta-tubulins. Int. J. Cancer 120(10), 2078-2085 (2007).
51. Mozzetti S, Ferlini C, Concolino P et al. Class III beta-tubulin overexpression is a prominent mechanism of paclitaxel resistance in ovarian cancer patients. Clin. Cancer Res. 11(1), 298-305 (2005).
52. Ferrandina G, Zannoni GF, Martinelli E et al. Class III beta-tubulin overexpression is a marker of poor clinical outcome in advanced ovarian cancer patients. Clin. Cancer Res. 12(9), 2774-2779 (2006).
53. Ohishi Y, Oda Y, Basaki Y et al. Expression of beta-tubulin isotypes in human primary ovarian carcinoma. Gynecol. Oncol. 105(3), 586-592 (2007).
54. Aoki D, Oda Y, Hattori S et al. Overexpression of class III beta-tubulin predicts good response to taxane-based chemotherapy in ovarian clear cell adenocarcinoma. Clin. Cancer Res. 15(4), 1473-1480 (2009).
55. Urano N, Fujiwara Y, Doki Y et al. Clinical significance of class III beta-tubulin expression and its predictive value for resistance to docetaxel-based chemotherapy in gastric cancer. Int. J. Oncol. 28(2), 375-381 (2006).
56. Sève P, Reiman T, Lai R et al. Class III beta-tubulin is a marker of paclitaxel resistance in carcinomas of unknown primary site. Cancer Chemother. Pharmacol. 60(1), 27-34 (2007).
57. Rouzier R, Rajan R, Wagner P et al. Microtubule-associated protein tau: a marker of paclitaxel sensitivity in breast cancer. Proc. Natl Acad. Sci. USA 102(23), 8315-8320 (2005).
58. Wagner P, Wang B, Clark E, Lee H, Rouzier R, Pusztai L. Microtubule associated protein (MAP)-Tau: a novel mediator of paclitaxel sensitivity in vitro and in vivo. Cell Cycle 4(9), 1149-1152 (2005).
59. Andre F, Hatzis C, Anderson K et al. Microtubule-associated protein-tau is a bifunctional predictor of endocrine sensitivity and chemotherapy resistance in estrogen receptor-positive breast cancer. Clin. Cancer Res. 13(7), 2061-2067 (2007).
60. Pusztai L, Symmans FW, Hortobagyi GN. Development of pharmacogenomic markers to select preoperative chemotherapy for breast cancer. Breast Cancer 12(2), 73-85 (2005).
61. Pentheroudakis G, Kalogeras KT, Wirtz RM et al. Gene expression of estrogen receptor, progesterone receptor and microtubule-associated protein Tau in high-risk early breast cancer: a quest for molecular predictors of treatment benefit in the context of a Hellenic Cooperative Oncology Group trial. Breast Cancer Res. Treat. 116(1), 131-143 (2009).
62. Chen X, Wu J, Lu H, Huang O, Shen K. Measuring beta-tubulin III, Bcl-2, and ERCC1 improves pathological complete remission predictive accuracy in breast cancer. Cancer Sci. 103(2), 262-268 (2012).
63. Gerth K, Bedorf N, Höfle G, Irschik H, Reichenbach H. Epothilons A and B: antifungal and cytotoxic compounds from Sorangium cellulosum (Myxobacteria). Production, physico-chemical and biological properties. J. Antibiot. 49(6), 560-563 (1996).
64. Ojima I, Chakravarty S, Inoue T et al. A common pharmacophore for cytotoxic natural products that stabilize microtubules. Proc. Natl Acad. Sci. USA 96(8), 4256-4261 (1999).
65. Nettles JH, Li H, Cornett B, Krahn JM, Snyder JP, Downing KH. The binding mode of epothilone A on alpha,beta-tubulin by electron crystallography. Science 305(5685), 866-869 (2004).
66. Bode CJ, Gupta ML Jr, Reiff EA, Suprenant KA, Georg GI, Himes RH. Epothilone and paclitaxel: unexpected differences in promoting the assembly and stabilization of yeast microtubules. Biochemistry 41(12), 3870-3874 (2002).
67. Kowalski RJ, Giannakakou P, Hamel E. Activities of the microtubule-stabilizing agents epothilones A and B with purified tubulin and in cells resistant to paclitaxel (Taxol(R)). J. Biol. Chem. 272(4), 2534-2541 (1997).
68. Lee FY, Borzilleri R, Fairchild CR et al. BMS-247550: a novel epothilone analog with a mode of action similar to paclitaxel but possessing superior antitumor efficacy. Clin. Cancer Res. 7(5), 1429-1437 (2001).
69. Lee FY, Borzilleri R, Fairchild CR et al. Preclinical discovery of ixabepilone, a highly active antineoplastic agent. Cancer Chemother. Pharmacol. 63(1), 157-166 (2008).
70. Mozzetti S, Ferlini C, Concolino P et al. Class III beta-tubulin overexpression is a prominent mechanism of paclitaxel resistance in ovarian cancer patients. Clin. Cancer Res. 11(1), 298-305 (2005).
71. Lee FY, Smykla R, Johnston K et al. Preclinical efficacy spectrum and pharmacokinetics of ixabepilone. Cancer Chemother. Pharmacol. 63(2), 201-212 (2009).
72. Roché H, Yelle L, Cognetti F et al. Phase II clinical trial of ixabepilone (BMS-247550), an epothilone B analog, as first-line therapy in patients with metastatic breast cancer previously treated with anthracycline chemotherapy. J. Clin. Oncol. 25(23), 3415-3420 (2007).
73. Thomas E, Tabernero J, Fornier M et al. Phase II clinical trial of ixabepilone (BMS-247550), an epothilone B analog, in patients with taxane-resistant metastatic breast cancer. J. Clin. Oncol. 25(23), 3399-3406 (2007).
74. Perez EA, Lerzo G, Pivot X et al. Efficacy and safety of ixabepilone (BMS-247550) in a Phase II study of patients with advanced breast cancer resistant to an anthracycline, a taxane, and capecitabine. J. Clin. Oncol. 25(23), 3407-3414 (2007).
75. Bunnell C, Vahdat L, Schwartzberg L et al. Phase I/II study of ixabepilone plus capecitabine in anthracycline-pretreated/ resistant and taxane-resistant metastatic breast cancer. Clin. Breast Cancer 8(3), 234-241 (2008).
76. Sparano JA, Vrdoljak E, Rixe O et al. Randomized Phase III trial of ixabepilone plus capecitabine versus capecitabine in patients with metastatic breast cancer previously treated with an anthracycline and a taxane. J. Clin. Oncol. 28(20), 3256-3263 (2010).
77. Thomas ES, Gomez HL, Li RK et al. Ixabepilone plus capecitabine for metastatic breast cancer progressing after anthracycline and taxane treatment. J. Clin. Oncol. 25(33), 5210-5217 (2007).
78. Ho J, Zhang L, Todorova L, Whillans F, Corey-Lisle P, Yuan Y. Budget impact analysis of ixabepilone used according to FDA approved labeling in treatment-resistant metastatic breast cancer. J. Manag. Care Pharm. 15(6), 467-475 (2009).
79. Hillner BE, Smith TJ. Efficacy does not necessarily translate to cost effectiveness: a case study in the challenges associated with 21st-century cancer drug pricing. J. Clin. Oncol. 27(13), 2111-2113 (2009).
80. Hirata YUD, Uemera D. Halichondrins - antitumor polyether macrolides from a marine sponge. Pure Appl. Chem. 58(5), 701-710 (1986).
81. Bai RL, Paull KD, Herald CL, Malspeis L, Pettit GR, Hamel E. Halichondrin B and homohalichondrin B, marine natural products binding in the vinca domain of tubulin. Discovery of tubulin-based mechanism of action by analysis of differential cytotoxicity data. J. Biol. Chem. 266(24), 15882-15889 (1991).
82. Fodstad O, Breistøl K, Pettit GR, Shoemaker RH, Boyd MR. Comparative antitumor activities of halichondrins and vinblastine against human tumor xenografts. J. Exp. Ther. Oncol. 1(2), 119-125 (1996).
83. Towle MJ, Salvato KA, Budrow J et al. In vitro and in vivo anticancer activities of synthetic macrocyclic ketone analogues of halichondrin B. Cancer Res. 61(3), 1013-1021 (2001).
84. Zheng W, Seletsky BM, Palme MH et al. Macrocyclic ketone analogues of halichondrin B. Bioorg. Med. Chem. 14(22), 5551-5554 (2004).
85. Smith JA, Wilson L, Azarenko O, et al. Eribulin binds at microtubule ends to a single site on tubulin to suppress dynamic instability. Biochemistry 49(6), 1331-1337 (2010).
86. Towle MJ, Salvato KA, Budrow J et al. In vitro and in vivo anticancer activities of synthetic macrocyclic ketone analogues of halichondrin B. Cancer Res. 61(3), 1013-1021 (2001).
87. Tan AR, Rubin EH, Walton DC et al. Phase I study of eribulin mesylate administered once every 21 days in patients with advanced solid tumors. Clin. Cancer Res. 15(12), 4213-4219 (2009).
88. Mukohara T, Nagai S, Mukai H, Namiki M, Minami H. Eribulin mesylate in patients with refractory cancers: a Phase I study. Invest. N. Drugs 30(5), 1926-1933 (2012).
89. Cortes J, Vahdat L, Blum JL et al. Phase II study of the halichondrin B analog eribulin mesylate in patients with locally advanced or metastatic breast cancer previously treated with an anthracycline, a taxane, and capecitabine. J. Clin. Oncol. 28(25), 3922-3928 (2010).
90. Vahdat LT, Pruitt B, Fabian CJ et al. Phase II study of eribulin mesylate, a halichondrin B analog, in patients with metastatic breast cancer previously treated with an anthracycline and a taxane. J. Clin. Oncol. 27(18), 2954-2961 (2009).
91. Aogi K, Iwata H, Masuda N et al. A phase II study of eribulin in Japanese patients with heavily pretreated metastatic breast cancer. Ann. Oncol. 23(6), 1441-1448 (2012).
92. Twelves C, Cortes J, Vahdat LT, Wanders J, Akerele C, Kaufman PA. Phase III trials of eribulin mesylate (E7389) in extensively pretreated patients with locally recurrent or metastatic breast cancer. Clin. Breast Cancer 10(2), 160-163 (2010).
93. Nasim MP, Jeffry E, Morrison R et al. A Phase Ib dose-escalation study of eribulin mesylate in combination with capecitabine in patients with advanced/metastatic cancer. J. Clin. Oncol. 30, Abstract 2552 (2012).
94. Zatloukal P, Gervais R, Vansteenkiste J et al. Randomized multicenter Phase II study of larotaxel (XRP9881) in combination with cisplatin or gemcitabine as first-line chemotherapy in nonirradiable stage IIIB or stage IV non-small cell lung cancer. J. Thorac. Oncol. 3(8), 894-901 (2008).
95. Diéras V, Limentani S, Romieu G et al. Phase II multicenter study of larotaxel (XRP9881), a novel taxoid, in patients with metastatic breast cancer who previously received taxane-based therapy. Ann. Oncol. 19(7), 1255-1260 (2008).
96. Kato K, Chin K, Yoshikawa T et al. Phase II study of NK105, a paclitaxel-incorporating micellar nanoparticle, for previously treated advanced or recurrent gastric cancer. Invest. N. Drugs 30(4), 1621-1627 (2012).
97. Ramanathan RK, Picus J, Raftopoulos H et al. A Phase II study of milataxel: a novel taxane analogue in previously treated patients with advanced colorectal cancer. Cancer Chemother. Pharmacol. 61(3), 453-458 (2008).
98. Bedikian AY, DeConti RC, Conry R et al. Phase III study of docosahexaenoic acid-paclitaxel versus dacarbazine in patients with metastatic malignant melanoma. Ann. Oncol. 22(4), 787-793 (2011).
99. Seidman AD, Schwartzberg LS, O'Shaughnessy J. Tesetaxel: Activity of an oral taxane as first-line treatment in metastatic breast cancer. J. Clin. Oncol. 30, Abstract 1016 (2012).
100. Sanofi-aventis. XRP6258 Investigator's Brochure. Sanofi-Aventis. Antony, France (2000).
101. Hunter J, Jepson MA, Tsuruo T, Simmons NL, Hirst BH. Functional expression of P-glycoprotein in apical membranes of human intestinal Caco-2 cells. Kinetics of vinblastine secretion and interaction with modulators. J. Biol. Chem. 268(20), 14991-14997 (1993).
102. Mita AC, Denis LJ, Rowinsky EK et al. Phase I and pharmacokinetic study of XRP6258 (RPR 116258A), a novel taxane, administered as a 1-hour infusion every 3 weeks in patients with advanced solid tumors. Clin. Cancer Res. 15(2), 723-730 (2009).
103. Pivot X, Koralewski P, Hidalgo JL et al. A multicenter Phase II study of XRP6258 administered as a 1-h i.v. infusion every 3 weeks in taxane-resistant metastatic breast cancer patients. Ann. Oncol. 19(9), 1547-1552 (2008).
104. de Bono JS, Oudard S, Ozguroglu M et al. Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial. Lancet 376(9747), 1147-1154 (2010).
105. de Bono JS, Logothetis CJ, Molina A et al. Abiraterone and increased survival in metastatic prostate cancer. N. Engl. J. Med., 364(21), 1995-2005 (2011).
106. Fang J, Sawa T, Maeda H. Factors and mechanism of 'EPR' effect and the enhanced antitumor effects of macromolecular drugs including SMANCS. Adv Exp. Med Biol. 519, 29-49 (2003).
107. John TA, Vogel SM, Tiruppathi C, Malik AB, Minshall RD. Quantitative analysis of albumin uptake and transport in the rat microvessel endothelial monolayer. Am. J. Physiol. Lung Cell. Mol. Physiol. 284(1), L187-L196 (2003).
108. Von Hoff DD, Ramanathan RK, Borad MJ et al. Gemcitabine plus nab-paclitaxel is an active regimen in patients with advanced pancreatic cancer: a phase I/II trial. J. Clin. Oncol. 29(34), 4548-4554 (2011).
109. Gradishar WJ, Tjulandin S, Davidson N et al. Phase III trial of nanoparticle albumin-bound paclitaxel compared with polyethylated castor oil-based paclitaxel in women with breast cancer. J. Clin. Oncol. 23(31), 7794-7803 (2005).
110. Gradishar WJ, Krasnojon D, Cheporov S et al. Significantly longer progression-free survival with nab-paclitaxel compared with docetaxel as first-line therapy for metastatic breast cancer. J. Clin. Oncol. 27(22), 3611-3619 (2009).
111. Rugo HS, Barry WT, Moreno-Aspitia A et al. CALGB 40502/NCCTG N063H: Randomized phase III trial of weekly paclitaxel (P) compared to weekly nanoparticle albumin bound nab-paclitaxel (NP) or ixabepilone (Ix) with or without bevacizumab (B) as first-line therapy for locally recurrent or metastatic breast cancer (MBC). J. Clin. Oncol. 30(Suppl.), Abstract CRA1002 (2012).
112. Blackwell KL, Burstein HJ, Storniolo AM et al. Randomized study of lapatinib alone or in combination with trastuzumab in women with ErbB2-positive, trastuzumab-refractory metastatic breast cancer. J. Clin. Oncol. 28(7), 1124-1130 (2010).
113. Nahta R, Yuan LX, Zhang B, Kobayashi R, Esteva FJ. Insulin-like growth factor-I receptor/human epidermal growth factor receptor 2 heterodimerization contributes to trastuzumab resistance of breast cancer cells. Cancer Res. 65(23), 11118-11128 (2005).
114. Geyer CE, Forster J, Lindquist D et al. Lapatinib plus capecitabine for HER2- positive advanced breast cancer. N. Engl. J. Med. 355(26), 2733-2743 (2006).
115. Lewis Phillips GD, Li G, Dugger DL et al. Targeting HER2-positive breast cancer with trastuzumab-DM1, an antibody-cytotoxic drug conjugate. Cancer Res. 68(22), 9280-9290 (2008).
116. Erickson HK, Park PU, Widdison WC et al. Antibody-maytansinoid conjugates are activated in targeted cancer cells by lysosomal degradation and linker-dependent intracellular processing. Cancer Res. 66(8), 4426-4433 (2006).
117. Barok M, Tanner M, Köninki K, Isola J. Trastuzumab-DM1 causes tumour growth inhibition by mitotic catastrophe in trastuzumab-resistant breast cancer cells in vivo. Breast Cancer Res. 13(2), R46 (2011).
118. Krop IE, Beeram M, Modi S et al. Phase I study of trastuzumab-DM1, an HER2 antibody-drug conjugate, given every 3 weeks to patients with HER2-positive metastatic breast cancer. J. Clin. Oncol. 28(16), 2698-2704 (2010).
119. Burris HA 3rd, Rugo HS, Vukelja SJ et al. Phase II study of the antibody drug conjugate trastuzumab-DM1 for the treatment of human epidermal growth factor receptor 2 (HER2)-positive breast cancer after prior HER2-directed therapy. J. Clin. Oncol. 29(4), 398-405 (2011).
120. Krop IE, LoRusso P, Miller KD et al. A Phase II study of trastuzumab emtansine in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer who were previously treated with trastuzumab, lapatinib, an anthracycline, a taxane, and capecitabine. J. Clin. Oncol. 30(26), 3234-3241 (2012).
121. Perez EA, Dirix L, Kocsis J et al. Efficacy and safety of trastuzumab-DM1 vs trastuzumab plus docetaxel in HER2-positive metastatic breast cancer patients with no prior chemotherapy for metastatic disease: preliminary results of a randomized, multicenter, open-label Phase 2 study (TDM4450G). Ann. Oncol. 21(Suppl. viii2), Abstract LBA3 (2010).
122. Verma S, Miles D, Gianni L et al. Trastuzumab emtansine for HER2-positive advanced breast cancer. N. Engl. J. Med. 367(19), 1783-1791 (2012).
123. Iyer AK, Khaled G, Fang J, Maeda H. Exploiting the enhanced permeability and retention effect for tumor targeting. Drug Discov. Today 11(17-18), 812-818 (2006).
124. Li C, Newman RA, Wu QP et al. Biodistribution of paclitaxel and poly(l-glutamic acid)-paclitaxel conjugate in mice with ovarian OCa-1 tumor. Cancer Chem. Pharmacol. 46(5), 416-422 (2000).
125. Shaffer SA, Baker-Lee C, Kennedy J et al. In vitro and in vivo metabolism of paclitaxel poliglumex: identification of metabolites and active proteases. Cancer Chemother. Pharmacol. 59(4), 537-548 (2007).
126. Langer CJ, O'Byrne KJ, Socinski MA et al. Phase III trial comparing paclitaxel poliglumex (CT-2103, PPX) in combination with carboplatin versus standard paclitaxel and carboplatin in the treatment of PS 2 patients with chemotherapy-naive advanced non-small cell lung cancer. J. Thorac. Oncol. 3(6), 623-630 (2008).
127. O'Brien ME, Socinski MA, Popovich AY et al. Randomized Phase III trial comparing single-agent paclitaxel Poliglumex (CT-2103, PPX) with single-agent gemcitabine or vinorelbine for the treatment of PS 2 patients with chemotherapy-naive advanced non-small cell lung cancer. J. Thorac. Oncol. 3(7), 728-734 (2008).
128. Paz-Ares L, Ross H, O'Brien M et al. Phase III trial comparing paclitaxel poliglumex vs docetaxel in the second-line treatment of non-small-cell lung cancer. Br. J. Cancer 98(10), 1608-1613 (2008).
129. Bissett D, Cassidy J, de Bono JS et al. Phase I and pharmacokinetic (PK) study of MAG-CPT (PNU 166148): a polymeric derivative of camptothecin (CPT). Br. J. Cancer 91(1), 50-55 (2004).